Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496308 | 0.85 | DRD2 (0.46) | MEN1KMT2AKDM4EL3MBTL1GRM5 | |
| SCHEMBL6495856 | 0.84 | MEN1 (0.40) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6502758 | 0.77 | NPC1 (0.56) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6493715 | 0.74 | NPC1 (0.43) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL7385161 | 0.73 | BUB1 (0.49) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6497908 | 0.72 | NPC1 (0.41) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6494383 | 0.70 | RXFP1 (0.40) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6309170 | 0.70 | MEN1 (0.42) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6834487 | 0.70 | GAA (0.43) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL6309523 | 0.69 | MEN1 (0.43) | NPC1RAB9AMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861529-B2 | Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors | PFIZER INC (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1404316-A1 | CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2003004018-A1 | CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069416-A1 | Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | GABARAP, GABRA3, GABRA2 | NPC1 2192/4885RAB9A 2858/4885MEN1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.